nodes	percent_of_prediction	percent_of_DWPC	metapath
Minocycline—CASP1—atopic dermatitis	0.594	0.75	CbGaD
Minocycline—IL1B—atopic dermatitis	0.199	0.25	CbGaD
Minocycline—IL1B—dermis—atopic dermatitis	0.0127	0.191	CbGeAlD
Minocycline—MMP9—dermis—atopic dermatitis	0.0106	0.159	CbGeAlD
Minocycline—CASP3—skin epidermis—atopic dermatitis	0.00669	0.1	CbGeAlD
Minocycline—IL1B—skin epidermis—atopic dermatitis	0.00534	0.0802	CbGeAlD
Minocycline—MMP9—skin epidermis—atopic dermatitis	0.00445	0.0668	CbGeAlD
Minocycline—CYCS—neck—atopic dermatitis	0.00374	0.0561	CbGeAlD
Minocycline—CASP3—neck—atopic dermatitis	0.0032	0.0481	CbGeAlD
Minocycline—CASP1—skin of body—atopic dermatitis	0.00251	0.0377	CbGeAlD
Minocycline—CYCS—skin of body—atopic dermatitis	0.00242	0.0363	CbGeAlD
Minocycline—MMP9—neck—atopic dermatitis	0.00213	0.032	CbGeAlD
Minocycline—CASP3—skin of body—atopic dermatitis	0.00207	0.0311	CbGeAlD
Minocycline—IL1B—skin of body—atopic dermatitis	0.00165	0.0248	CbGeAlD
Minocycline—CASP1—head—atopic dermatitis	0.00164	0.0246	CbGeAlD
Minocycline—CYCS—head—atopic dermatitis	0.00158	0.0237	CbGeAlD
Minocycline—MMP9—skin of body—atopic dermatitis	0.00138	0.0207	CbGeAlD
Minocycline—CASP3—head—atopic dermatitis	0.00135	0.0203	CbGeAlD
Minocycline—IL1B—head—atopic dermatitis	0.00108	0.0162	CbGeAlD
Minocycline—MMP9—head—atopic dermatitis	0.0009	0.0135	CbGeAlD
Minocycline—ALOX5—head—atopic dermatitis	0.000711	0.0107	CbGeAlD
Minocycline—CYCS—Ketotifen—Loratadine—atopic dermatitis	0.000508	0.0979	CbGdCrCtD
Minocycline—SLC22A8—head—atopic dermatitis	0.000481	0.00722	CbGeAlD
Minocycline—IL1B—Methylprednisolone—Desonide—atopic dermatitis	0.000256	0.0494	CbGdCrCtD
Minocycline—IL1B—Methylprednisolone—Fluocinonide—atopic dermatitis	0.000205	0.0396	CbGdCrCtD
Minocycline—IL1B—Methylprednisolone—Fluocinolone Acetonide—atopic dermatitis	0.0002	0.0385	CbGdCrCtD
Minocycline—IL1B—Methylprednisolone—Mometasone—atopic dermatitis	0.000159	0.0307	CbGdCrCtD
Minocycline—IL1B—Fluorometholone—Desonide—atopic dermatitis	0.000159	0.0306	CbGdCrCtD
Minocycline—CYCS—Sirolimus—Tacrolimus—atopic dermatitis	0.000134	0.0259	CbGdCrCtD
Minocycline—CYCS—Sirolimus—Pimecrolimus—atopic dermatitis	0.000134	0.0259	CbGdCrCtD
Minocycline—CYCS—Temsirolimus—Pimecrolimus—atopic dermatitis	0.000134	0.0259	CbGdCrCtD
Minocycline—CYCS—Temsirolimus—Tacrolimus—atopic dermatitis	0.000134	0.0259	CbGdCrCtD
Minocycline—IL1B—Fluorometholone—Fluocinonide—atopic dermatitis	0.000127	0.0245	CbGdCrCtD
Minocycline—IL1B—Fluorometholone—Fluocinolone Acetonide—atopic dermatitis	0.000124	0.0238	CbGdCrCtD
Minocycline—IL1B—Budesonide—Desonide—atopic dermatitis	0.000106	0.0204	CbGdCrCtD
Minocycline—IL1B—Methylprednisolone—Hydrocortisone—atopic dermatitis	0.000101	0.0194	CbGdCrCtD
Minocycline—IL1B—Fluorometholone—Mometasone—atopic dermatitis	9.87e-05	0.019	CbGdCrCtD
Minocycline—CASP3—Allograft Rejection—TNF—atopic dermatitis	9.75e-05	0.000722	CbGpPWpGaD
Minocycline—CASP3—Alzheimers Disease—TNF—atopic dermatitis	9.75e-05	0.000722	CbGpPWpGaD
Minocycline—CASP3—Spinal Cord Injury—IL1B—atopic dermatitis	9.74e-05	0.000721	CbGpPWpGaD
Minocycline—CASP3—Spinal Cord Injury—IL2—atopic dermatitis	9.71e-05	0.000719	CbGpPWpGaD
Minocycline—CASP3—Integrated Pancreatic Cancer Pathway—NFKBIA—atopic dermatitis	9.69e-05	0.000717	CbGpPWpGaD
Minocycline—CASP3—MAPK Signaling Pathway—CASP8—atopic dermatitis	9.68e-05	0.000717	CbGpPWpGaD
Minocycline—MMP9—Regulation of nuclear beta catenin signaling and target gene transcription—CXCL8—atopic dermatitis	9.62e-05	0.000712	CbGpPWpGaD
Minocycline—MMP9—CXCR4-mediated signaling events—CD4—atopic dermatitis	9.61e-05	0.000712	CbGpPWpGaD
Minocycline—IL1B—Signaling by Interleukins—IL2—atopic dermatitis	9.43e-05	0.000698	CbGpPWpGaD
Minocycline—ALOX5—Selenium Micronutrient Network—IL1B—atopic dermatitis	9.41e-05	0.000697	CbGpPWpGaD
Minocycline—VEGFA—SIDS Susceptibility Pathways—BDNF—atopic dermatitis	9.38e-05	0.000694	CbGpPWpGaD
Minocycline—IL1B—Methylprednisolone—Betamethasone—atopic dermatitis	9.36e-05	0.018	CbGdCrCtD
Minocycline—IL1B—Methylprednisolone—Dexamethasone—atopic dermatitis	9.36e-05	0.018	CbGdCrCtD
Minocycline—VEGFA—VEGFR2 mediated cell proliferation—IL6—atopic dermatitis	9.3e-05	0.000689	CbGpPWpGaD
Minocycline—IL1B—Immune System—FCER1A—atopic dermatitis	9.3e-05	0.000688	CbGpPWpGaD
Minocycline—CASP3—Apoptosis—TNF—atopic dermatitis	9.28e-05	0.000687	CbGpPWpGaD
Minocycline—VEGFA—Platelet activation, signaling and aggregation—IL5—atopic dermatitis	9.27e-05	0.000686	CbGpPWpGaD
Minocycline—IL1B—Spinal Cord Injury—CXCL8—atopic dermatitis	9.19e-05	0.000681	CbGpPWpGaD
Minocycline—IL1B—Methylprednisolone—Triamcinolone—atopic dermatitis	9.14e-05	0.0176	CbGdCrCtD
Minocycline—IL1B—Toll-like Receptor Signaling Pathway—MAPK8—atopic dermatitis	9.09e-05	0.000673	CbGpPWpGaD
Minocycline—VEGFA—Allograft Rejection—IFNG—atopic dermatitis	9.07e-05	0.000672	CbGpPWpGaD
Minocycline—VEGFA—Aryl Hydrocarbon Receptor—TNF—atopic dermatitis	9.05e-05	0.00067	CbGpPWpGaD
Minocycline—MMP9—TWEAK Signaling Pathway—IL6—atopic dermatitis	9.05e-05	0.00067	CbGpPWpGaD
Minocycline—VEGFA—SIDS Susceptibility Pathways—IL10—atopic dermatitis	8.95e-05	0.000663	CbGpPWpGaD
Minocycline—CYCS—Apoptosis—MAPK8—atopic dermatitis	8.9e-05	0.000659	CbGpPWpGaD
Minocycline—CASP1—Signaling by Interleukins—IL6—atopic dermatitis	8.87e-05	0.000657	CbGpPWpGaD
Minocycline—IL1B—Alzheimers Disease—TNF—atopic dermatitis	8.82e-05	0.000653	CbGpPWpGaD
Minocycline—IL1B—Allograft Rejection—TNF—atopic dermatitis	8.82e-05	0.000653	CbGpPWpGaD
Minocycline—IL1B—Spinal Cord Injury—IL2—atopic dermatitis	8.79e-05	0.000651	CbGpPWpGaD
Minocycline—IL1B—MAPK Signaling Pathway—CASP8—atopic dermatitis	8.77e-05	0.000649	CbGpPWpGaD
Minocycline—CASP3—Integrated Pancreatic Cancer Pathway—CASP8—atopic dermatitis	8.74e-05	0.000647	CbGpPWpGaD
Minocycline—IL1B—Methylprednisolone—Prednisone—atopic dermatitis	8.68e-05	0.0167	CbGdCrCtD
Minocycline—VEGFA—Oncostatin M Signaling Pathway—MAPK8—atopic dermatitis	8.68e-05	0.000642	CbGpPWpGaD
Minocycline—SLC22A8—SLC-mediated transmembrane transport—SLC11A1—atopic dermatitis	8.66e-05	0.000641	CbGpPWpGaD
Minocycline—IL1B—Immune System—MS4A2—atopic dermatitis	8.64e-05	0.00064	CbGpPWpGaD
Minocycline—CASP3—TNF alpha Signaling Pathway—TNF—atopic dermatitis	8.63e-05	0.000639	CbGpPWpGaD
Minocycline—CASP3—Signaling by NGF—NGF—atopic dermatitis	8.51e-05	0.00063	CbGpPWpGaD
Minocycline—IL1B—Budesonide—Fluocinonide—atopic dermatitis	8.5e-05	0.0164	CbGdCrCtD
Minocycline—IL1B—Methylprednisolone—Prednisolone—atopic dermatitis	8.47e-05	0.0163	CbGdCrCtD
Minocycline—IL1B—Cytokine Signaling in Immune system—IL18—atopic dermatitis	8.46e-05	0.000626	CbGpPWpGaD
Minocycline—VEGFA—Allograft Rejection—CXCL8—atopic dermatitis	8.44e-05	0.000625	CbGpPWpGaD
Minocycline—CASP1—Immune System—STAT6—atopic dermatitis	8.38e-05	0.00062	CbGpPWpGaD
Minocycline—VEGFA—SIDS Susceptibility Pathways—NGF—atopic dermatitis	8.32e-05	0.000616	CbGpPWpGaD
Minocycline—IL1B—Budesonide—Fluocinolone Acetonide—atopic dermatitis	8.26e-05	0.0159	CbGdCrCtD
Minocycline—IL1B—Folate Metabolism—IL6—atopic dermatitis	8.22e-05	0.000609	CbGpPWpGaD
Minocycline—CASP1—Immune System—CARD11—atopic dermatitis	8.15e-05	0.000604	CbGpPWpGaD
Minocycline—CASP3—SIDS Susceptibility Pathways—CXCL8—atopic dermatitis	8.12e-05	0.000602	CbGpPWpGaD
Minocycline—VEGFA—Allograft Rejection—IL1B—atopic dermatitis	8.09e-05	0.000599	CbGpPWpGaD
Minocycline—IL1B—Selenium Micronutrient Network—TNF—atopic dermatitis	8.09e-05	0.000599	CbGpPWpGaD
Minocycline—IL1B—Regulation of toll-like receptor signaling pathway—CXCL8—atopic dermatitis	8.06e-05	0.000597	CbGpPWpGaD
Minocycline—VEGFA—Allograft Rejection—IL2—atopic dermatitis	8.06e-05	0.000597	CbGpPWpGaD
Minocycline—VEGFA—Integrated Pancreatic Cancer Pathway—BDNF—atopic dermatitis	7.98e-05	0.000591	CbGpPWpGaD
Minocycline—CASP1—Cytokine Signaling in Immune system—IFNG—atopic dermatitis	7.92e-05	0.000587	CbGpPWpGaD
Minocycline—VEGFA—Hemostasis—KIF3A—atopic dermatitis	7.82e-05	0.000579	CbGpPWpGaD
Minocycline—CASP3—SIDS Susceptibility Pathways—IL1B—atopic dermatitis	7.79e-05	0.000577	CbGpPWpGaD
Minocycline—CYCS—Metabolism—GLB1—atopic dermatitis	7.78e-05	0.000576	CbGpPWpGaD
Minocycline—CASP1—MAPK Signaling Pathway—TNF—atopic dermatitis	7.72e-05	0.000571	CbGpPWpGaD
Minocycline—IL1B—Immune System—DEFB1—atopic dermatitis	7.7e-05	0.00057	CbGpPWpGaD
Minocycline—CASP3—BDNF signaling pathway—MAPK8—atopic dermatitis	7.62e-05	0.000564	CbGpPWpGaD
Minocycline—MMP9—Spinal Cord Injury—IFNG—atopic dermatitis	7.58e-05	0.000561	CbGpPWpGaD
Minocycline—CYCS—Metabolism—ADSL—atopic dermatitis	7.46e-05	0.000552	CbGpPWpGaD
Minocycline—IL1B—SIDS Susceptibility Pathways—CXCL8—atopic dermatitis	7.35e-05	0.000544	CbGpPWpGaD
Minocycline—CASP3—MAPK Signaling Pathway—IL1B—atopic dermatitis	7.35e-05	0.000544	CbGpPWpGaD
Minocycline—SLC22A6—SLC-mediated transmembrane transport—SLC11A1—atopic dermatitis	7.23e-05	0.000535	CbGpPWpGaD
Minocycline—IL1B—Toll-like Receptor Signaling Pathway—TNF—atopic dermatitis	7.19e-05	0.000532	CbGpPWpGaD
Minocycline—CASP3—Apoptosis—MAPK8—atopic dermatitis	7.18e-05	0.000532	CbGpPWpGaD
Minocycline—IL1B—Regulation of toll-like receptor signaling pathway—MAPK8—atopic dermatitis	7.09e-05	0.000525	CbGpPWpGaD
Minocycline—CASP3—Spinal Cord Injury—TNF—atopic dermatitis	7.07e-05	0.000523	CbGpPWpGaD
Minocycline—CASP1—Cytokine Signaling in Immune system—IL1B—atopic dermatitis	7.07e-05	0.000523	CbGpPWpGaD
Minocycline—VEGFA—Differentiation Pathway—IL6—atopic dermatitis	7.06e-05	0.000523	CbGpPWpGaD
Minocycline—MMP9—Spinal Cord Injury—CXCL8—atopic dermatitis	7.05e-05	0.000522	CbGpPWpGaD
Minocycline—CYCS—Apoptosis—TNF—atopic dermatitis	7.04e-05	0.000522	CbGpPWpGaD
Minocycline—CASP1—Cytokine Signaling in Immune system—IL2—atopic dermatitis	7.04e-05	0.000521	CbGpPWpGaD
Minocycline—CASP3—Signaling by NGF—NFKBIA—atopic dermatitis	7.01e-05	0.000519	CbGpPWpGaD
Minocycline—CASP3—TNF alpha Signaling Pathway—IL6—atopic dermatitis	6.96e-05	0.000516	CbGpPWpGaD
Minocycline—ALOX5—Selenium Micronutrient Network—TNF—atopic dermatitis	6.83e-05	0.000505	CbGpPWpGaD
Minocycline—MMP9—Spinal Cord Injury—IL1B—atopic dermatitis	6.76e-05	0.000501	CbGpPWpGaD
Minocycline—MMP9—Spinal Cord Injury—IL2—atopic dermatitis	6.74e-05	0.000499	CbGpPWpGaD
Minocycline—CASP3—MAPK Signaling Pathway—MAPK8—atopic dermatitis	6.74e-05	0.000499	CbGpPWpGaD
Minocycline—CASP3—Signaling Pathways—FCER2—atopic dermatitis	6.64e-05	0.000492	CbGpPWpGaD
Minocycline—CYCS—Cellular responses to stress—CXCL8—atopic dermatitis	6.61e-05	0.000489	CbGpPWpGaD
Minocycline—IL1B—Budesonide—Mometasone—atopic dermatitis	6.59e-05	0.0127	CbGdCrCtD
Minocycline—IL1B—Selenium Micronutrient Network—IL6—atopic dermatitis	6.53e-05	0.000483	CbGpPWpGaD
Minocycline—IL1B—Betamethasone—Desonide—atopic dermatitis	6.49e-05	0.0125	CbGdCrCtD
Minocycline—IL1B—Dexamethasone—Desonide—atopic dermatitis	6.49e-05	0.0125	CbGdCrCtD
Minocycline—IL1B—TCR Signaling Pathway—IL6—atopic dermatitis	6.41e-05	0.000475	CbGpPWpGaD
Minocycline—IL1B—Spinal Cord Injury—TNF—atopic dermatitis	6.4e-05	0.000474	CbGpPWpGaD
Minocycline—VEGFA—Integrated Breast Cancer Pathway—CASP8—atopic dermatitis	6.36e-05	0.000471	CbGpPWpGaD
Minocycline—VEGFA—Hemostasis—SELE—atopic dermatitis	6.3e-05	0.000467	CbGpPWpGaD
Minocycline—IL1B—Fluorometholone—Hydrocortisone—atopic dermatitis	6.24e-05	0.012	CbGdCrCtD
Minocycline—CASP3—Signaling Pathways—CCL22—atopic dermatitis	6.17e-05	0.000457	CbGpPWpGaD
Minocycline—IL1B—Immune System—KIF3A—atopic dermatitis	6.16e-05	0.000456	CbGpPWpGaD
Minocycline—IL1B—MAPK Signaling Pathway—MAPK8—atopic dermatitis	6.1e-05	0.000451	CbGpPWpGaD
Minocycline—CASP3—Integrated Pancreatic Cancer Pathway—MAPK8—atopic dermatitis	6.08e-05	0.00045	CbGpPWpGaD
Minocycline—VEGFA—SHP2 signaling—IL6—atopic dermatitis	6.07e-05	0.000449	CbGpPWpGaD
Minocycline—CASP1—Immune System—IL5—atopic dermatitis	6.02e-05	0.000446	CbGpPWpGaD
Minocycline—MMP9—AP-1 transcription factor network—IL6—atopic dermatitis	6.01e-05	0.000445	CbGpPWpGaD
Minocycline—IL1B—Fluorometholone—Methylprednisolone—atopic dermatitis	5.89e-05	0.0114	CbGdCrCtD
Minocycline—VEGFA—Allograft Rejection—TNF—atopic dermatitis	5.87e-05	0.000435	CbGpPWpGaD
Minocycline—VEGFA—Integrated Pancreatic Cancer Pathway—NFKBIA—atopic dermatitis	5.84e-05	0.000432	CbGpPWpGaD
Minocycline—CYCS—Cellular responses to stress—MAPK8—atopic dermatitis	5.81e-05	0.00043	CbGpPWpGaD
Minocycline—IL1B—Toll-like Receptor Signaling Pathway—IL6—atopic dermatitis	5.8e-05	0.00043	CbGpPWpGaD
Minocycline—IL1B—Fluorometholone—Betamethasone—atopic dermatitis	5.8e-05	0.0112	CbGdCrCtD
Minocycline—IL1B—Fluorometholone—Dexamethasone—atopic dermatitis	5.8e-05	0.0112	CbGdCrCtD
Minocycline—CASP1—Innate Immune System—NFKBIA—atopic dermatitis	5.79e-05	0.000429	CbGpPWpGaD
Minocycline—SLC22A11—Transmembrane transport of small molecules—SLC11A1—atopic dermatitis	5.77e-05	0.000427	CbGpPWpGaD
Minocycline—CASP1—Immune System—TLR2—atopic dermatitis	5.74e-05	0.000425	CbGpPWpGaD
Minocycline—CASP3—Spinal Cord Injury—IL6—atopic dermatitis	5.71e-05	0.000422	CbGpPWpGaD
Minocycline—CASP3—Apoptosis—TNF—atopic dermatitis	5.68e-05	0.000421	CbGpPWpGaD
Minocycline—IL1B—Senescence and Autophagy in Cancer—IL6—atopic dermatitis	5.67e-05	0.00042	CbGpPWpGaD
Minocycline—IL1B—Fluorometholone—Triamcinolone—atopic dermatitis	5.67e-05	0.0109	CbGdCrCtD
Minocycline—CASP3—SIDS Susceptibility Pathways—TNF—atopic dermatitis	5.66e-05	0.000419	CbGpPWpGaD
Minocycline—IL1B—Regulation of toll-like receptor signaling pathway—TNF—atopic dermatitis	5.61e-05	0.000416	CbGpPWpGaD
Minocycline—CYCS—Alimemazine—Diphenhydramine—atopic dermatitis	5.6e-05	0.0108	CbGdCrCtD
Minocycline—IL1B—Signaling by Interleukins—IL6—atopic dermatitis	5.54e-05	0.00041	CbGpPWpGaD
Minocycline—ALOX5—Selenium Micronutrient Network—IL6—atopic dermatitis	5.51e-05	0.000408	CbGpPWpGaD
Minocycline—CASP3—Signaling Pathways—CCL27—atopic dermatitis	5.5e-05	0.000407	CbGpPWpGaD
Minocycline—CASP1—Immune System—CD79A—atopic dermatitis	5.4e-05	0.0004	CbGpPWpGaD
Minocycline—CYCS—Transmembrane transport of small molecules—PPARA—atopic dermatitis	5.39e-05	0.000399	CbGpPWpGaD
Minocycline—IL1B—Fluorometholone—Prednisone—atopic dermatitis	5.38e-05	0.0104	CbGdCrCtD
Minocycline—CASP3—MAPK Signaling Pathway—TNF—atopic dermatitis	5.33e-05	0.000395	CbGpPWpGaD
Minocycline—VEGFA—Integrated Pancreatic Cancer Pathway—CASP8—atopic dermatitis	5.27e-05	0.00039	CbGpPWpGaD
Minocycline—IL1B—Fluorometholone—Prednisolone—atopic dermatitis	5.25e-05	0.0101	CbGdCrCtD
Minocycline—SLC22A7—Transmembrane transport of small molecules—SLC11A1—atopic dermatitis	5.24e-05	0.000388	CbGpPWpGaD
Minocycline—IL1B—Immune System—STAT6—atopic dermatitis	5.24e-05	0.000388	CbGpPWpGaD
Minocycline—CASP1—Innate Immune System—CASP8—atopic dermatitis	5.23e-05	0.000387	CbGpPWpGaD
Minocycline—IL1B—Betamethasone—Fluocinonide—atopic dermatitis	5.2e-05	0.01	CbGdCrCtD
Minocycline—IL1B—Dexamethasone—Fluocinonide—atopic dermatitis	5.2e-05	0.01	CbGdCrCtD
Minocycline—IL1B—Spinal Cord Injury—IL6—atopic dermatitis	5.16e-05	0.000382	CbGpPWpGaD
Minocycline—IL1B—SIDS Susceptibility Pathways—TNF—atopic dermatitis	5.12e-05	0.000379	CbGpPWpGaD
Minocycline—IL1B—Immune System—CARD11—atopic dermatitis	5.09e-05	0.000377	CbGpPWpGaD
Minocycline—VEGFA—Carbinoxamine—Diphenhydramine—atopic dermatitis	5.06e-05	0.00976	CbGdCrCtD
Minocycline—IL1B—Dexamethasone—Fluocinolone Acetonide—atopic dermatitis	5.05e-05	0.00973	CbGdCrCtD
Minocycline—IL1B—Betamethasone—Fluocinolone Acetonide—atopic dermatitis	5.05e-05	0.00973	CbGdCrCtD
Minocycline—IL1B—Cytokine Signaling in Immune system—IFNG—atopic dermatitis	4.95e-05	0.000367	CbGpPWpGaD
Minocycline—CASP3—Signaling Pathways—CCL17—atopic dermatitis	4.94e-05	0.000365	CbGpPWpGaD
Minocycline—MMP9—Spinal Cord Injury—TNF—atopic dermatitis	4.91e-05	0.000363	CbGpPWpGaD
Minocycline—VEGFA—SIDS Susceptibility Pathways—CXCL8—atopic dermatitis	4.9e-05	0.000362	CbGpPWpGaD
Minocycline—IL1B—MAPK Signaling Pathway—TNF—atopic dermatitis	4.82e-05	0.000357	CbGpPWpGaD
Minocycline—CASP3—Integrated Pancreatic Cancer Pathway—TNF—atopic dermatitis	4.81e-05	0.000356	CbGpPWpGaD
Minocycline—ALOX5—Metabolism—GLB1—atopic dermatitis	4.79e-05	0.000355	CbGpPWpGaD
Minocycline—VEGFA—Hemostasis—IL5—atopic dermatitis	4.78e-05	0.000354	CbGpPWpGaD
Minocycline—VEGFA—SIDS Susceptibility Pathways—IL1B—atopic dermatitis	4.7e-05	0.000348	CbGpPWpGaD
Minocycline—MMP9—Signaling Pathways—FCER2—atopic dermatitis	4.61e-05	0.000341	CbGpPWpGaD
Minocycline—ALOX5—Metabolism—ADSL—atopic dermatitis	4.6e-05	0.00034	CbGpPWpGaD
Minocycline—CASP3—SIDS Susceptibility Pathways—IL6—atopic dermatitis	4.56e-05	0.000338	CbGpPWpGaD
Minocycline—IL1B—Regulation of toll-like receptor signaling pathway—IL6—atopic dermatitis	4.53e-05	0.000335	CbGpPWpGaD
Minocycline—CASP1—Immune System—IL18—atopic dermatitis	4.42e-05	0.000327	CbGpPWpGaD
Minocycline—SLC22A8—Transmembrane transport of small molecules—SLC11A1—atopic dermatitis	4.4e-05	0.000326	CbGpPWpGaD
Minocycline—IL1B—Cytokine Signaling in Immune system—IL2—atopic dermatitis	4.4e-05	0.000326	CbGpPWpGaD
Minocycline—CASP3—Signaling by NGF—MAPK8—atopic dermatitis	4.4e-05	0.000326	CbGpPWpGaD
Minocycline—CASP3—Signaling Pathways—KIF3A—atopic dermatitis	4.4e-05	0.000326	CbGpPWpGaD
Minocycline—CASP1—Immune System—CD8A—atopic dermatitis	4.35e-05	0.000322	CbGpPWpGaD
Minocycline—CYCS—Clomifene—Diphenhydramine—atopic dermatitis	4.31e-05	0.0083	CbGdCrCtD
Minocycline—CASP1—Innate Immune System—CD4—atopic dermatitis	4.29e-05	0.000318	CbGpPWpGaD
Minocycline—MMP9—Signaling Pathways—CCL22—atopic dermatitis	4.29e-05	0.000317	CbGpPWpGaD
Minocycline—IL1B—Budesonide—Hydrocortisone—atopic dermatitis	4.17e-05	0.00804	CbGdCrCtD
Minocycline—IL1B—Myometrial Relaxation and Contraction Pathways—IL6—atopic dermatitis	4.15e-05	0.000307	CbGpPWpGaD
Minocycline—CASP1—Cytokine Signaling in Immune system—IL6—atopic dermatitis	4.14e-05	0.000306	CbGpPWpGaD
Minocycline—IL1B—SIDS Susceptibility Pathways—IL6—atopic dermatitis	4.13e-05	0.000306	CbGpPWpGaD
Minocycline—IL1B—Dexamethasone—Mometasone—atopic dermatitis	4.03e-05	0.00777	CbGdCrCtD
Minocycline—IL1B—Betamethasone—Mometasone—atopic dermatitis	4.03e-05	0.00777	CbGdCrCtD
Minocycline—VEGFA—Signaling Pathways—FCER2—atopic dermatitis	4e-05	0.000296	CbGpPWpGaD
Minocycline—CASP3—Signaling Pathways—CCL11—atopic dermatitis	3.98e-05	0.000295	CbGpPWpGaD
Minocycline—CASP3—Signaling Pathways—CMA1—atopic dermatitis	3.98e-05	0.000295	CbGpPWpGaD
Minocycline—IL1B—Immune System—CASP1—atopic dermatitis	3.97e-05	0.000294	CbGpPWpGaD
Minocycline—MMP9—Spinal Cord Injury—IL6—atopic dermatitis	3.96e-05	0.000293	CbGpPWpGaD
Minocycline—IL1B—Budesonide—Methylprednisolone—atopic dermatitis	3.93e-05	0.00758	CbGdCrCtD
Minocycline—IL1B—Budesonide—Dexamethasone—atopic dermatitis	3.87e-05	0.00746	CbGdCrCtD
Minocycline—IL1B—Budesonide—Betamethasone—atopic dermatitis	3.87e-05	0.00746	CbGdCrCtD
Minocycline—MMP9—Signaling Pathways—CCL27—atopic dermatitis	3.82e-05	0.000283	CbGpPWpGaD
Minocycline—IL1B—Budesonide—Triamcinolone—atopic dermatitis	3.78e-05	0.00729	CbGdCrCtD
Minocycline—IL1B—Immune System—IL5—atopic dermatitis	3.76e-05	0.000279	CbGpPWpGaD
Minocycline—CASP3—Signaling Pathways—STAT6—atopic dermatitis	3.74e-05	0.000277	CbGpPWpGaD
Minocycline—VEGFA—Signaling Pathways—CCL22—atopic dermatitis	3.72e-05	0.000275	CbGpPWpGaD
Minocycline—VEGFA—VEGFA-VEGFR2 Pathway—IL6—atopic dermatitis	3.72e-05	0.000275	CbGpPWpGaD
Minocycline—CYCS—Cellular responses to stress—IL6—atopic dermatitis	3.71e-05	0.000275	CbGpPWpGaD
Minocycline—VEGFA—Focal Adhesion—MAPK8—atopic dermatitis	3.68e-05	0.000272	CbGpPWpGaD
Minocycline—SLC22A6—Transmembrane transport of small molecules—SLC11A1—atopic dermatitis	3.67e-05	0.000272	CbGpPWpGaD
Minocycline—VEGFA—Integrated Pancreatic Cancer Pathway—MAPK8—atopic dermatitis	3.66e-05	0.000271	CbGpPWpGaD
Minocycline—CASP1—Innate Immune System—MAPK8—atopic dermatitis	3.63e-05	0.000269	CbGpPWpGaD
Minocycline—IL1B—Budesonide—Prednisone—atopic dermatitis	3.59e-05	0.00692	CbGdCrCtD
Minocycline—IL1B—Immune System—TLR2—atopic dermatitis	3.59e-05	0.000266	CbGpPWpGaD
Minocycline—MMP9—Developmental Biology—PPARA—atopic dermatitis	3.56e-05	0.000263	CbGpPWpGaD
Minocycline—VEGFA—Platelet activation, signaling and aggregation—IL2—atopic dermatitis	3.54e-05	0.000262	CbGpPWpGaD
Minocycline—VEGFA—Signaling by VEGF—IL6—atopic dermatitis	3.51e-05	0.00026	CbGpPWpGaD
Minocycline—IL1B—Budesonide—Prednisolone—atopic dermatitis	3.5e-05	0.00675	CbGdCrCtD
Minocycline—ALOX5—Metabolism of lipids and lipoproteins—PPARA—atopic dermatitis	3.49e-05	0.000259	CbGpPWpGaD
Minocycline—VEGFA—Dexamethasone—Desonide—atopic dermatitis	3.46e-05	0.00668	CbGdCrCtD
Minocycline—VEGFA—Betamethasone—Desonide—atopic dermatitis	3.46e-05	0.00668	CbGdCrCtD
Minocycline—MMP9—Signaling by SCF-KIT—IL6—atopic dermatitis	3.43e-05	0.000254	CbGpPWpGaD
Minocycline—MMP9—Signaling Pathways—CCL17—atopic dermatitis	3.43e-05	0.000254	CbGpPWpGaD
Minocycline—VEGFA—SIDS Susceptibility Pathways—TNF—atopic dermatitis	3.41e-05	0.000252	CbGpPWpGaD
Minocycline—IL1B—Immune System—CD79A—atopic dermatitis	3.37e-05	0.00025	CbGpPWpGaD
Minocycline—CASP1—Immune System—NFKBIA—atopic dermatitis	3.37e-05	0.00025	CbGpPWpGaD
Minocycline—VEGFA—Signaling Pathways—CCL27—atopic dermatitis	3.32e-05	0.000246	CbGpPWpGaD
Minocycline—CASP3—Signaling Pathways—CCR3—atopic dermatitis	3.24e-05	0.00024	CbGpPWpGaD
Minocycline—VEGFA—Cellular responses to stress—CXCL8—atopic dermatitis	3.21e-05	0.000238	CbGpPWpGaD
Minocycline—VEGFA—Developmental Biology—PPARA—atopic dermatitis	3.09e-05	0.000229	CbGpPWpGaD
Minocycline—MMP9—Signaling Pathways—KIF3A—atopic dermatitis	3.05e-05	0.000226	CbGpPWpGaD
Minocycline—CASP1—Immune System—CASP8—atopic dermatitis	3.04e-05	0.000225	CbGpPWpGaD
Minocycline—VEGFA—Signaling Pathways—CCL17—atopic dermatitis	2.97e-05	0.00022	CbGpPWpGaD
Minocycline—VEGFA—Integrated Pancreatic Cancer Pathway—TNF—atopic dermatitis	2.9e-05	0.000215	CbGpPWpGaD
Minocycline—CASP3—Signaling Pathways—NPS—atopic dermatitis	2.89e-05	0.000214	CbGpPWpGaD
Minocycline—CASP3—Signaling Pathways—TAC1—atopic dermatitis	2.89e-05	0.000214	CbGpPWpGaD
Minocycline—CASP3—Signaling Pathways—CXCR3—atopic dermatitis	2.84e-05	0.00021	CbGpPWpGaD
Minocycline—VEGFA—Cellular responses to stress—MAPK8—atopic dermatitis	2.83e-05	0.000209	CbGpPWpGaD
Minocycline—CASP3—Signaling by NGF—IL6—atopic dermatitis	2.81e-05	0.000208	CbGpPWpGaD
Minocycline—SLC22A11—Transmembrane transport of small molecules—PPARA—atopic dermatitis	2.8e-05	0.000207	CbGpPWpGaD
Minocycline—VEGFA—Dexamethasone—Fluocinonide—atopic dermatitis	2.77e-05	0.00535	CbGdCrCtD
Minocycline—VEGFA—Betamethasone—Fluocinonide—atopic dermatitis	2.77e-05	0.00535	CbGdCrCtD
Minocycline—CYCS—Tamoxifen—Diphenhydramine—atopic dermatitis	2.76e-05	0.00533	CbGdCrCtD
Minocycline—MMP9—Signaling Pathways—CMA1—atopic dermatitis	2.76e-05	0.000205	CbGpPWpGaD
Minocycline—MMP9—Signaling Pathways—CCL11—atopic dermatitis	2.76e-05	0.000205	CbGpPWpGaD
Minocycline—IL1B—Immune System—IL18—atopic dermatitis	2.76e-05	0.000204	CbGpPWpGaD
Minocycline—VEGFA—SIDS Susceptibility Pathways—IL6—atopic dermatitis	2.75e-05	0.000204	CbGpPWpGaD
Minocycline—IL1B—Immune System—CD8A—atopic dermatitis	2.72e-05	0.000201	CbGpPWpGaD
Minocycline—VEGFA—Dexamethasone—Fluocinolone Acetonide—atopic dermatitis	2.7e-05	0.0052	CbGdCrCtD
Minocycline—VEGFA—Betamethasone—Fluocinolone Acetonide—atopic dermatitis	2.7e-05	0.0052	CbGdCrCtD
Minocycline—CASP3—Signaling Pathways—IL5—atopic dermatitis	2.69e-05	0.000199	CbGpPWpGaD
Minocycline—VEGFA—Signaling Pathways—KIF3A—atopic dermatitis	2.65e-05	0.000196	CbGpPWpGaD
Minocycline—MMP9—Signaling Pathways—STAT6—atopic dermatitis	2.6e-05	0.000192	CbGpPWpGaD
Minocycline—CASP1—Immune System—IFNG—atopic dermatitis	2.59e-05	0.000192	CbGpPWpGaD
Minocycline—IL1B—Cytokine Signaling in Immune system—IL6—atopic dermatitis	2.59e-05	0.000192	CbGpPWpGaD
Minocycline—IL1B—Dexamethasone—Hydrocortisone—atopic dermatitis	2.55e-05	0.00492	CbGdCrCtD
Minocycline—IL1B—Betamethasone—Hydrocortisone—atopic dermatitis	2.55e-05	0.00492	CbGdCrCtD
Minocycline—SLC22A7—Transmembrane transport of small molecules—PPARA—atopic dermatitis	2.54e-05	0.000188	CbGpPWpGaD
Minocycline—CYCS—Metabolism—PPARA—atopic dermatitis	2.53e-05	0.000187	CbGpPWpGaD
Minocycline—CASP1—Immune System—CD4—atopic dermatitis	2.5e-05	0.000185	CbGpPWpGaD
Minocycline—IL1B—Dexamethasone—Methylprednisolone—atopic dermatitis	2.41e-05	0.00464	CbGdCrCtD
Minocycline—IL1B—Betamethasone—Methylprednisolone—atopic dermatitis	2.41e-05	0.00464	CbGdCrCtD
Minocycline—VEGFA—Signaling Pathways—CMA1—atopic dermatitis	2.4e-05	0.000178	CbGpPWpGaD
Minocycline—VEGFA—Signaling Pathways—CCL11—atopic dermatitis	2.4e-05	0.000178	CbGpPWpGaD
Minocycline—IL1B—Dexamethasone—Betamethasone—atopic dermatitis	2.37e-05	0.00456	CbGdCrCtD
Minocycline—IL1B—Betamethasone—Dexamethasone—atopic dermatitis	2.37e-05	0.00456	CbGdCrCtD
Minocycline—CASP1—Innate Immune System—IL6—atopic dermatitis	2.32e-05	0.000172	CbGpPWpGaD
Minocycline—IL1B—Dexamethasone—Triamcinolone—atopic dermatitis	2.31e-05	0.00446	CbGdCrCtD
Minocycline—IL1B—Betamethasone—Triamcinolone—atopic dermatitis	2.31e-05	0.00446	CbGdCrCtD
Minocycline—CASP1—Immune System—IL1B—atopic dermatitis	2.31e-05	0.000171	CbGpPWpGaD
Minocycline—CASP1—Immune System—IL2—atopic dermatitis	2.3e-05	0.00017	CbGpPWpGaD
Minocycline—CASP3—Signaling Pathways—CXCL10—atopic dermatitis	2.29e-05	0.00017	CbGpPWpGaD
Minocycline—VEGFA—Signaling Pathways—STAT6—atopic dermatitis	2.25e-05	0.000167	CbGpPWpGaD
Minocycline—MMP9—Signaling Pathways—CCR3—atopic dermatitis	2.25e-05	0.000167	CbGpPWpGaD
Minocycline—IL1B—Betamethasone—Prednisone—atopic dermatitis	2.2e-05	0.00423	CbGdCrCtD
Minocycline—IL1B—Dexamethasone—Prednisone—atopic dermatitis	2.2e-05	0.00423	CbGdCrCtD
Minocycline—VEGFA—Dexamethasone—Mometasone—atopic dermatitis	2.15e-05	0.00415	CbGdCrCtD
Minocycline—VEGFA—Betamethasone—Mometasone—atopic dermatitis	2.15e-05	0.00415	CbGdCrCtD
Minocycline—IL1B—Betamethasone—Prednisolone—atopic dermatitis	2.14e-05	0.00413	CbGdCrCtD
Minocycline—IL1B—Dexamethasone—Prednisolone—atopic dermatitis	2.14e-05	0.00413	CbGdCrCtD
Minocycline—SLC22A8—Transmembrane transport of small molecules—PPARA—atopic dermatitis	2.13e-05	0.000158	CbGpPWpGaD
Minocycline—CASP1—Immune System—MAPK8—atopic dermatitis	2.12e-05	0.000157	CbGpPWpGaD
Minocycline—IL1B—Immune System—NFKBIA—atopic dermatitis	2.11e-05	0.000156	CbGpPWpGaD
Minocycline—MMP9—Signaling Pathways—NPS—atopic dermatitis	2.01e-05	0.000149	CbGpPWpGaD
Minocycline—MMP9—Signaling Pathways—TAC1—atopic dermatitis	2.01e-05	0.000149	CbGpPWpGaD
Minocycline—CASP3—Signaling Pathways—CCL5—atopic dermatitis	1.97e-05	0.000146	CbGpPWpGaD
Minocycline—MMP9—Signaling Pathways—CXCR3—atopic dermatitis	1.97e-05	0.000146	CbGpPWpGaD
Minocycline—VEGFA—Signaling Pathways—CCR3—atopic dermatitis	1.95e-05	0.000145	CbGpPWpGaD
Minocycline—IL1B—Immune System—CASP8—atopic dermatitis	1.9e-05	0.000141	CbGpPWpGaD
Minocycline—MMP9—Signaling Pathways—IL5—atopic dermatitis	1.87e-05	0.000138	CbGpPWpGaD
Minocycline—CASP3—Signaling Pathways—NGF—atopic dermatitis	1.83e-05	0.000135	CbGpPWpGaD
Minocycline—VEGFA—Hemostasis—IL2—atopic dermatitis	1.83e-05	0.000135	CbGpPWpGaD
Minocycline—VEGFA—Cellular responses to stress—IL6—atopic dermatitis	1.81e-05	0.000134	CbGpPWpGaD
Minocycline—SLC22A6—Transmembrane transport of small molecules—PPARA—atopic dermatitis	1.78e-05	0.000132	CbGpPWpGaD
Minocycline—CASP3—Signaling Pathways—CCR5—atopic dermatitis	1.78e-05	0.000132	CbGpPWpGaD
Minocycline—MMP9—Axon guidance—IL6—atopic dermatitis	1.77e-05	0.000131	CbGpPWpGaD
Minocycline—VEGFA—Signaling Pathways—NPS—atopic dermatitis	1.74e-05	0.000129	CbGpPWpGaD
Minocycline—VEGFA—Signaling Pathways—TAC1—atopic dermatitis	1.74e-05	0.000129	CbGpPWpGaD
Minocycline—VEGFA—Signaling Pathways—CXCR3—atopic dermatitis	1.71e-05	0.000126	CbGpPWpGaD
Minocycline—VEGFA—Signaling Pathways—IL5—atopic dermatitis	1.62e-05	0.00012	CbGpPWpGaD
Minocycline—IL1B—Immune System—IFNG—atopic dermatitis	1.62e-05	0.00012	CbGpPWpGaD
Minocycline—MMP9—Signaling Pathways—CXCL10—atopic dermatitis	1.59e-05	0.000118	CbGpPWpGaD
Minocycline—IL1B—Immune System—CD4—atopic dermatitis	1.56e-05	0.000116	CbGpPWpGaD
Minocycline—MMP9—Developmental Biology—TNF—atopic dermatitis	1.56e-05	0.000116	CbGpPWpGaD
Minocycline—ALOX5—Metabolism—PPARA—atopic dermatitis	1.56e-05	0.000115	CbGpPWpGaD
Minocycline—VEGFA—Axon guidance—IL6—atopic dermatitis	1.53e-05	0.000113	CbGpPWpGaD
Minocycline—CASP3—Signaling Pathways—NFKBIA—atopic dermatitis	1.51e-05	0.000112	CbGpPWpGaD
Minocycline—IL1B—Immune System—IL2—atopic dermatitis	1.44e-05	0.000106	CbGpPWpGaD
Minocycline—VEGFA—Signaling Pathways—CXCL10—atopic dermatitis	1.38e-05	0.000102	CbGpPWpGaD
Minocycline—MMP9—Signaling Pathways—CCL5—atopic dermatitis	1.37e-05	0.000101	CbGpPWpGaD
Minocycline—VEGFA—Dexamethasone—Hydrocortisone—atopic dermatitis	1.36e-05	0.00262	CbGdCrCtD
Minocycline—VEGFA—Betamethasone—Hydrocortisone—atopic dermatitis	1.36e-05	0.00262	CbGdCrCtD
Minocycline—VEGFA—Developmental Biology—TNF—atopic dermatitis	1.36e-05	0.0001	CbGpPWpGaD
Minocycline—CASP1—Immune System—IL6—atopic dermatitis	1.35e-05	0.0001	CbGpPWpGaD
Minocycline—IL1B—Immune System—MAPK8—atopic dermatitis	1.32e-05	9.8e-05	CbGpPWpGaD
Minocycline—CYCS—Levonorgestrel—Hydrocortisone—atopic dermatitis	1.3e-05	0.00251	CbGdCrCtD
Minocycline—VEGFA—Betamethasone—Methylprednisolone—atopic dermatitis	1.29e-05	0.00248	CbGdCrCtD
Minocycline—VEGFA—Dexamethasone—Methylprednisolone—atopic dermatitis	1.29e-05	0.00248	CbGdCrCtD
Minocycline—MMP9—Signaling Pathways—NGF—atopic dermatitis	1.27e-05	9.39e-05	CbGpPWpGaD
Minocycline—VEGFA—Betamethasone—Dexamethasone—atopic dermatitis	1.26e-05	0.00244	CbGdCrCtD
Minocycline—VEGFA—Dexamethasone—Betamethasone—atopic dermatitis	1.26e-05	0.00244	CbGdCrCtD
Minocycline—MMP9—Developmental Biology—IL6—atopic dermatitis	1.26e-05	9.33e-05	CbGpPWpGaD
Minocycline—VEGFA—Dexamethasone—Triamcinolone—atopic dermatitis	1.24e-05	0.00238	CbGdCrCtD
Minocycline—VEGFA—Betamethasone—Triamcinolone—atopic dermatitis	1.24e-05	0.00238	CbGdCrCtD
Minocycline—MMP9—Signaling Pathways—CCR5—atopic dermatitis	1.23e-05	9.13e-05	CbGpPWpGaD
Minocycline—VEGFA—Signaling Pathways—CCL5—atopic dermatitis	1.19e-05	8.8e-05	CbGpPWpGaD
Minocycline—VEGFA—Dexamethasone—Prednisone—atopic dermatitis	1.17e-05	0.00226	CbGdCrCtD
Minocycline—VEGFA—Betamethasone—Prednisone—atopic dermatitis	1.17e-05	0.00226	CbGdCrCtD
Minocycline—VEGFA—Dexamethasone—Prednisolone—atopic dermatitis	1.14e-05	0.00221	CbGdCrCtD
Minocycline—VEGFA—Betamethasone—Prednisolone—atopic dermatitis	1.14e-05	0.00221	CbGdCrCtD
Minocycline—VEGFA—Signaling Pathways—NGF—atopic dermatitis	1.1e-05	8.15e-05	CbGpPWpGaD
Minocycline—VEGFA—Developmental Biology—IL6—atopic dermatitis	1.09e-05	8.1e-05	CbGpPWpGaD
Minocycline—CASP3—Signaling Pathways—CXCL8—atopic dermatitis	1.07e-05	7.96e-05	CbGpPWpGaD
Minocycline—VEGFA—Signaling Pathways—CCR5—atopic dermatitis	1.07e-05	7.93e-05	CbGpPWpGaD
Minocycline—MMP9—Signaling Pathways—NFKBIA—atopic dermatitis	1.05e-05	7.74e-05	CbGpPWpGaD
Minocycline—CASP3—Signaling Pathways—IL2—atopic dermatitis	1.03e-05	7.6e-05	CbGpPWpGaD
Minocycline—CASP3—Signaling Pathways—MAPK8—atopic dermatitis	9.45e-06	7e-05	CbGpPWpGaD
Minocycline—VEGFA—Signaling Pathways—NFKBIA—atopic dermatitis	9.08e-06	6.72e-05	CbGpPWpGaD
Minocycline—IL1B—Immune System—IL6—atopic dermatitis	8.45e-06	6.26e-05	CbGpPWpGaD
Minocycline—MMP9—Signaling Pathways—CXCL8—atopic dermatitis	7.46e-06	5.52e-05	CbGpPWpGaD
Minocycline—MMP9—Signaling Pathways—IL2—atopic dermatitis	7.13e-06	5.28e-05	CbGpPWpGaD
Minocycline—MMP9—Signaling Pathways—MAPK8—atopic dermatitis	6.56e-06	4.86e-05	CbGpPWpGaD
Minocycline—VEGFA—Signaling Pathways—CXCL8—atopic dermatitis	6.48e-06	4.79e-05	CbGpPWpGaD
Minocycline—VEGFA—Signaling Pathways—IL2—atopic dermatitis	6.19e-06	4.58e-05	CbGpPWpGaD
Minocycline—CASP3—Signaling Pathways—IL6—atopic dermatitis	6.04e-06	4.47e-05	CbGpPWpGaD
Minocycline—VEGFA—Signaling Pathways—MAPK8—atopic dermatitis	5.7e-06	4.22e-05	CbGpPWpGaD
Minocycline—MMP9—Signaling Pathways—IL6—atopic dermatitis	4.19e-06	3.1e-05	CbGpPWpGaD
Minocycline—VEGFA—Signaling Pathways—IL6—atopic dermatitis	3.64e-06	2.69e-05	CbGpPWpGaD
